Lyell Immunopharma (LYEL)

• Market cap: $320M
• 1 day: 0.79%
• 5 days: -5.66%
• 1 month: 2.59%
• 3 months: 41.07%
• 6 months: 75.37%
• Year to date: 29.15%
• 1 year: -13.27%
• 5 years: -95.07%
• 10 years: -95.07%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300